FDA Approves Remibrutinib as First Treatment for Symptomatic Dermographism

The FDA has approved remibrutinib (Rhapsido, Novartis) as the first and only treatment for adults with symptomatic dermographism (SD) inadequately controlled by standard antihistamines. This oral BTK inhibitor is also indicated for chronic spontaneous urticaria (CSU), making it the sole treatment for both common forms of chronic hives. This approval offers a new therapeutic option for patients suffering from these challenging skin conditions.